Home | Blog | Weight Loss | Can Weight Loss Injections Cause Pancreatitis?
There have been reports of acute pancreatitis in people taking weight loss injections containing GLP-1 receptor agonists – but are the two linked?
While prior evidence suggested there was no increased risk of pancreatitis when using weight loss injections, more research is currently being carried out to investigate the relationship between the two further.

GLP-1 stands for glucagon-like peptide 1, and it’s a naturally occurring hormone your body releases after eating. Weight loss injections like Wegovy and Mounjaro contain a medicine called a GLP-1 receptor agonist, which acts in the same way as naturally occurring GLP-1. This provides a few different benefits:
It increases the amount of insulin you release after eating, which can help manage type-2 diabetes.
It slows down how quickly food passes through the digestive system, and targets the part of your brain responsible for regulating appetite and satiety. This helps manage cravings and hunger, which can assist with weight loss.
There’s also evidence that GLP-1 treatments can reduce the risk of cardiovascular issues.
Pancreatitis is when your pancreas, an organ found behind your stomach, becomes inflamed. Your pancreas is a gland that makes insulin and digestive enzymes, to help you digest food and process the glucose from it. The main symptom of pancreatitis is pain in your upper abdomen that can spread through to your back.
There are two types of pancreatitis: acute and chronic. Acute pancreatitis is when your pancreas becomes inflamed for a short period of time, and gets better with a few days of treatment; this is the kind reportedly linked to weight loss injections. Chronic pancreatitis is a long-term condition that can cause damage to your pancreas over time.
There are several possible causes of pancreatitis. Sometimes it can be the secondary effect of a different health condition, but certain types of medications may be a contributing factor too.
Gallstones are one of the most common causes of pancreatitis. They form in your gallbladder, a small organ below your liver that stores bile. Bile is produced by your liver, and helps to digest fats in your diet. Large amounts of cholesterol (fats) can cause an imbalance in the chemical make-up of bile, which leads to crystals forming in the bile stored in your gallbladder. These can grow over many years into solid stones.
If a gallstone moves out of your gallbladder it can block the opening to your pancreas, causing it to become inflamed. This is how gallstones cause acute pancreatitis.
Alcohol consumption is another common cause of pancreatitis, and can lead to pancreatitis in a couple of different ways.
High triglyceride (also known as hypertriglyceridemia) levels are the next most common cause of pancreatitis after alcohol and gallstones. We don’t fully understand how high triglyceride levels cause pancreatitis. One of the leading theories is that an interaction between triglycerides and the digestive enzymes released by your pancreas can produce substances that may damage the pancreas, leading to pancreatitis.
While rapid weight loss itself isn’t thought to increase the risk of pancreatitis, some approaches to losing weight quickly can. One of these is the ketogenic (keto) diet – which involves eating very few or no carbohydrates at all.
The reason this helps you lose weight is also the reason it increases your risk of pancreatitis: without carbohydrates to use for energy, the body enters lipolysis, where it breaks down stored fats to release energy. But this also releases free fatty acids into your bloodstream, which are converted into triglycerides by your liver. This can increase your triglyceride levels, which could lead to acute pancreatitis due to hypertriglyceridemia.
The keto diet involves eating more dietary fat and fewer carbohydrates, to switch the body’s preferred source of energy from carbs to stored fat. But because most dietary fat is in the form of triglycerides, if you unknowingly eat any carbohydrates, your body can switch back to processing carbs for energy – leaving you with elevated triglyceride levels.
While eating little-to-no carbs may increase your risk of hypertriglyceridemia – eating too many can also have a similar effect. Studies show that when you eat more than the recommended level of dietary carbohydrates (over 55% of your energy intake), the concentration of triglycerides in your blood can rise. So it’s really important to maintain a healthy balance of carbs and dietary fat (whether you’re using GLP-1 treatment or not), to minimise your risk of pancreatitis.
There’s also a chance pancreatitis could be caused by a medication you’re taking. In a 2005 US review of prescription drugs associated with pancreatitis, the following medications were each found to be linked to over 20 reported cases of acute pancreatitis:
There’s evidence that pancreatitis can be hereditary, too. Hereditary pancreatitis tends to start with cases of acute pancreatitis in childhood, which then transitions to chronic pancreatitis in early adulthood. It’s thought that variations in the PRSS1 gene are the primary cause of acute pancreatitis, accounting for 60-85% of people with hereditary pancreatitis. But not everyone with hereditary pancreatitis will have an identifiable genetic cause, and variations in other genes that haven’t been identified yet could also be responsible.
Observational studies have reported a link between acute pancreatitis and type-2 diabetes for a long time. A 2010 study set out to gather more data on the topic – specifically on how diabetic treatment could affect pancreatitis caused by diabetes. The study identified 85,525 individuals with diabetes and 200,000 without, and asked about cases of acute pancreatitis.
243 cases were found in the general population, and 176 in the diabetes cohort – meaning there was a 30.1% incidence rate in the general population and a 54% incidence rate in the diabetes cohort. While it was noted that the level of association between diabetes and pancreatitis fell when adjusted for other factors that could cause pancreatitis, the study concluded that type-2 diabetes may be associated with an increased risk. It was also discovered that using insulin to treat type-2 diabetes could lower this risk, but further research is still needed.
Initial studies when GLP-1 agonists were first approved suggested there was no increased risk of acute pancreatitis in people using semaglutide. The SUSTAIN-6 trial for semaglutide found that it was associated with acute pancreatitis at the same rate as placebo.
But recent reports of pancreas problems in patients using GLP-1 receptor agonists have prompted new research to explore the link between the two.
Data collected by the MHRA has found that there were hundreds of cases of acute and chronic pancreatitis in people taking GLP-1 agonists – but made it clear that these cases were infrequent and it’s uncertain whether or not the medication was the cause.
Because GLP-1 receptor agonists are used to treat obesity and diabetes, and both obesity and diabetes are associated with an increased risk of pancreatitis, it can be difficult to determine whether the drug or the condition it’s treating is the cause.
The Yellow Card Biobank is looking to investigate the link between genetics and the risk of certain side effects. This would help prevent adverse side effects by checking whether or not you have a genetic predisposition to them before you take the medication. Dr. Alison Cave, the MHRA Chief Safety Officer, said that “almost a third of side effects to medicines could be prevented” with this kind of testing.
Whether you’re using GLP-1 receptor agonists or not, if you experience abdominal pain that spreads through to your back, alongside possible nausea and vomiting – you should seek medical attention right away. It may be a symptom of pancreatitis.
But it’s important to note that abdominal discomfort, nausea, and vomiting are all common and usually harmless side effects of GLP-1 receptor agonists – especially on your injection day. It’s when these symptoms get worse (with pain spreading through to your back) that you should see a doctor.
If you have any concerns about starting weight loss injections and developing pancreatitis, speak to your healthcare provider about your previous medical history. They’ll be able to advise you on whether or not GLP-1 receptor agonists are right for you. And if not, they may be able to recommend an alternative.
If you do get any pancreatic side effects while using GLP-1 receptor agonists, you should report them through the MHRA’s Yellow Card scheme. This will help improve the safety of similar medications in the future.
Acute Pancreatitis in a Patient Taking Semaglutide. Cureus. 15(8).
If you take a GLP-1 medicine and have been hospitalised by acute pancreatitis, the Yellow Card Biobank wants to hear from you. 26 June. gov.uk.
Glucagon-Like Peptide-1 Receptor Agonists. StatPearls. Treasure Island (FL): StatPearls Publishing.
What are the most common gallbladder problems? Healthline. December 18.
Alcoholic Pancreatitis. StatPearls. Treasure Island (FL): StatPearls Publishing.
Pancreatitis Secondary to Hypertriglyceridemia. In: Feingold KR, Ahmed SF, Anawalt B, et al., editors. Endotext. South Dartmouth (MA): MDText.com.
Inducing necrotizing pancreatitis associated with a ketogenic diet: A case report. Clinical Nutrition Open Science. 52. pp. 110-116.
Severe Hypertriglyceridemia-Induced Necrotizing Pancreatitis Associated With Ketogenic Diet in a Well-Controlled Patient With Type 2 Diabetes Mellitus. Cureus. 14(1).
Effect of Dietary Carbohydrate on Triglyceride Metabolism in Humans 1. The Journal of Nutrition. 131(10). pp. 2772S-2774S.
Drug-induced pancreatitis: an update. Journal of Clinical Gastroenterology. 39(8). pp. 709-16.
Familial and Hereditary Pancreatitis.
Acute Pancreatitis in Association With Type 2 Diabetes and Antidiabetic Drugs. Diabetes Care. 33(12). pp. 2580-2585.
Pancreatitis - acute: What are the risk factors and causes?. NICE.
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 375(19). pp. 1834-1844.
GLP-1 receptor agonists: MHRA to study possible side effects after acute pancreatitis cases. BMJ. 389.
How we source info.
When we present you with stats, data, opinion or a consensus, we’ll tell you where this came from. And we’ll only present data as clinically reliable if it’s come from a reputable source, such as a state or government-funded health body, a peer-reviewed medical journal, or a recognised analytics or data body. Read more in our editorial policy.
Have a subject you’d like us to cover in a future article? Let us know.
We're making healthcare more about you. Sign up to our newsletter for personalised health articles that make a difference.
Disclaimer: The information provided on this page is not a substitute for professional medical advice, diagnosis, or treatment. If you have any questions or concerns about your health, please talk to a doctor.
We couldn't find what you're looking for.
Here's everything we treat. Or, if you're looking for something we don't have yet, you can suggest something.
By clicking 'Subscribe now' you're agreeing to our Privacy Policy.
(And leave your email too, so we can let you know if we write an article based on your suggestion.)
Last updated on Jul 01, 2025.
Our experts continually monitor new findings in health and medicine, and we update our articles when new info becomes available.
Jul 01, 2025
Published by: The Treated Content Team. Medically reviewed by: Dr Alexandra Cristina Cowell, Writer & Clinical Content ReviewerHow we source info.
When we present you with stats, data, opinion or a consensus, we’ll tell you where this came from. And we’ll only present data as clinically reliable if it’s come from a reputable source, such as a state or government-funded health body, a peer-reviewed medical journal, or a recognised analytics or data body. Read more in our editorial policy.